SCHEMBL25195525

SCHEMBL25195525

Cc1cc(-c2ccc(C(F)(F)F)nc2N)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 1/20 0.41
▸ MAP4K4 O95819 3/20 0.41
▸ PSEN1 P49768 3/20 0.41
▸ PSEN2 P49810 3/20 0.41
▸ APH1B Q8WW43 3/20 0.41
▸ NCSTN Q92542 3/20 0.41
▸ APH1A Q96BI3 3/20 0.41
▸ PSENEN Q9NZ42 3/20 0.41
▸ S1PR1 P21453 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ PDE3B Q13370 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ PARP15 Q460N3 1/20 0.39
▸ PARP14 Q460N5 1/20 0.39
▸ PARP10 Q53GL7 1/20 0.39
▸ TIPARP Q7Z3E1 1/20 0.39
▸ PARP16 Q8N5Y8 1/20 0.39
▸ PARP11 Q9NR21 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30042674 1.00 PDK2 (0.41) PDK2MAP4K4PSEN1PSEN2APH1B
SCHEMBL30112165 0.86 MAP4K4 (0.50) MAP4K4PARP15PARP14PARP10TIPARP
SCHEMBL25222544 0.86 MAP4K4 (0.50) MAP4K4PARP15PARP14PARP10TIPARP
SCHEMBL16906525 0.72 PIK3CB (0.50) PDK2MAP4K4PSEN1PSEN2APH1B
SCHEMBL31729829 0.72 GLA (0.43) PDK2MAP4K4S1PR1PDE3BPDE3A
SCHEMBL26631657 0.70 PTGS2 (0.44) PDK2S1PR1HSP90AA1HSP90AB1
SCHEMBL6915992 0.69 PDE3B (0.48) PDK2MAP4K4PDE3BPDE3APIK3CB
SCHEMBL28267323 0.69 DHFR (0.51) MAP4K4PARP15PARP14PARP10TIPARP
SCHEMBL11621764 0.69 CCNC (0.40) PDK2MAP4K4PSEN1PSEN2APH1B
SCHEMBL31128383 0.69 PSEN1 (0.49) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617802-B2 Sulfonimidamide compounds as NLRP3 modulators GENENTECH, INC. (US) 2026-05-05 — — US disclosed
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS GENENTECH, INC. (US) 2023-05-25 — — US disclosed
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS GENENTECH, INC. (US) 2023-05-25 — — US disclosed
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS GENENTECH, INC. (US) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS NLRP3, NLRP1, PYCARD PDK2 2199/4885MAP4K4 1590/4885PSEN1 55/4885
US-12617802-B2 Sulfonimidamide compounds as NLRP3 modulators NLRP3, NLRP1, PYCARD PDK2 3812/4885MAP4K4 2516/4885PSEN1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback